8-K: Kyverna Prices $100M Public Offering

Kyverna Therapeutics announced the pricing of an underwritten public offering of 13,333,333 shares of common stock at $7.50 per share, expecting to raise approximately $100 million in gross proceeds.

Summary

• Kyverna Therapeutics, Inc. entered into an underwriting agreement for a public offering of 13,333,333 shares of common stock.
• The public offering price is $7.50 per share, with underwriters purchasing shares at $7.05 per share.
• The company granted underwriters a 30-day option to purchase up to an additional 1,999,999 shares of common stock.
• Gross proceeds from the offering are expected to be approximately $100 million, before deducting underwriting discounts, commissions, and offering expenses.
• Net proceeds are intended for general corporate purposes, including funding research and development, capital expenditures, working capital, and general and administrative expenses.
• The offering is expected to close on or about December 18, 2025, subject to customary closing conditions.
• J.P. Morgan Securities LLC, Leerink Partners LLC, Morgan Stanley & Co. LLC, and Wells Fargo Securities, LLC are acting as joint book-running managers for the offering.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the company successfully secured significant capital, which is crucial for a clinical-stage biopharmaceutical company. However, the offering involves substantial dilution for existing shareholders, which tempers the overall positive impact.

Positives

• The company successfully priced a significant public offering, securing approximately $100 million in gross proceeds.
• The capital raise provides funding for general corporate purposes, including critical research and development, capital expenditures, and working capital.
• The inclusion of a 30-day option for underwriters to purchase additional shares indicates potential for further capital if demand is strong.

Negatives

• The issuance of 13,333,333 new shares, with an option for nearly 2 million more, will result in dilution for existing shareholders.
• Underwriters are purchasing shares at $7.05, a discount of $0.45 per share from the public offering price of $7.50, representing underwriting discounts and commissions.

Risks

• The anticipated closing of the offering is subject to the company's ability to satisfy certain conditions on a timely basis or at all.
• Market conditions could impact the offering or the company's future performance.
• Other risks detailed from time to time in the company's periodic reports and other filings with the SEC could materially affect actual results.

Future Outlook

The company intends to use the net proceeds from the offering for general corporate purposes, which may include funding research and development, capital expenditures, working capital, and general and administrative expenses. The offering is expected to close on or about December 18, 2025.

Management Comments

• Kyverna Therapeutics, Inc. announced the pricing of an underwritten public offering of 13,333,333 shares of its common stock at a public offering price of $7.50 per share.
• Gross proceeds to Kyverna from the offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and offering expenses.

Industry Context

This filing does not provide specific industry context or comparisons to broader industry trends or competitors. It focuses solely on the company's capital raising activity.

Comparison to Industry Standards

• NA

Corporate Governance

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new common stock, potentially impacting earnings per share and ownership percentage.
• The company's operational capacity and ability to fund critical research and development, capital expenditures, and general operations will be significantly enhanced by the capital infusion.

Next Steps

• The closing of the offering is expected on or about December 18, 2025, subject to customary closing conditions.
• The company will apply the net proceeds for general corporate purposes, including research and development, capital expenditures, working capital, and general and administrative expenses.

Key Dates

Keywords

Kyverna Therapeutics, KYTX, Public Offering, Common Stock, Underwriting Agreement, Capital Raise, Biopharmaceutical, Cell Therapy, Autoimmune Diseases, Nasdaq